UNH

From a fundamental perspective, UnitedHealth demonstrates impressive growth metrics, with a staggering 1,181.4% revenue growth year-over-year, although the quarter-over-quarter revenue growth of 2.0% shows signs of slowing down. The company maintains robust margins, highlighted by a gross margin of 1,852.6% and an operating margin of 423.7%. The price-to-earnings (P/E) ratio stands at 30.2, while the forward P/E is more favorable at 21.9, suggesting that the stock may be reasonably valued in light of its anticipated growth. Analysts have a consensus rating of BUY, with 6 strong buy, 16 buy, 5 hold, and 1 sell. The average target price of $409.77 aligns closely with the current trading price, indicating limited upside potential in the short term.

UnitedHealth is set to report its next earnings on July 16, 2026, just within the 30-day window, making this an important catalyst to monitor. The most recent earnings report on March 31, 2026, showed a modest quarter-over-quarter growth in EPS of 0.7%, which could suggest a trend towards stabilization. Notably, the recent developments regarding the resolution of the FTC insulin pricing dispute may impact sentiment and market positioning. Investors should watch for any significant changes in revenue growth dynamics or margin expansion that may arise from ongoing strategic initiatives and market conditions.